Fresenius Kabi Oncology Limited

BSE: 532545
₹132.45
▲ 0.35 (0.26%)
Jan. 2, 2014 · BSE · bse_bhavcopy
Quality
—/100
Data unavailable
Valuation
—/100
Data unavailable
Momentum
89/100
Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
Data unavailable.
PE (TTM)
Data unavailable.
Price to Book
Data unavailable.
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
-0.6
Relative return vs Sector, qtr %
Data unavailable.
Free Cash Flow
Data unavailable.
EPS Growth (YoY)
Data unavailable.
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
Data unavailable.
Revenue Growth (YoY)
Data unavailable.
Current Ratio
Data unavailable (needs a filed half-yearly balance sheet).
Debt to Equity
Data unavailable (needs a filed half-yearly balance sheet).
Interest Coverage
Data unavailable.
Net Margin
Data unavailable.
Operating Margin (EBIT)
Data unavailable.
Operating Margin (TTM)
Data unavailable.
Return on Assets
Data unavailable.
Return on Capital Employed
Data unavailable (needs a filed half-yearly balance sheet).
Return on Equity
Data unavailable (needs a filed half-yearly balance sheet).

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Value and momentum

3 of 4 met
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.3%
Low 132.0000 · High 132.6000
1W return
0.4%
Low 131.1000 · High 132.6000
1M return
1.8%
Low 129.5500 · High 132.6000
52W return
19.3%
Low 93.1000 · High 161.4000
Lifetime High ₹186.7500 (June 30, 2010)
Lifetime Low ₹30.3500 (Oct. 27, 2008)

Full price history and technicals →

EMA & SMA

Bullish6
Bearish0
5D
132.1
10D
131.7
20D
131.3
50D
130.3
100D
128.5
200D
124.4

Delivery and volume

Day avg. delivery
95.4%
Week avg. delivery
95.5%
Month avg. delivery
95.4%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

132.35
Pivot
First resistance132.70
Second resistance132.95
Third resistance133.30
First support132.10
Second support131.75
Third support131.50
Day RSI66.1
Day MFI73.0
Day MACD0.52
Day MACD signal0.39

Beta

1M-0.04
3M0.12
1Y0.26
3Y0.66

Price change analysis

↑ 1.8%
Over 1 Month
LowHigh
129.55132.60
↑ 3.8%
Over 3 Months
LowHigh
120.25161.40
↑ 23.5%
Over 6 Months
LowHigh
102.20161.40
↑ 19.3%
Over 1 Year
LowHigh
93.10161.40
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Data unavailable.

Shareholding pattern / Ownership

Data unavailable.

Full shareholding pattern →

DateClientDealActionQuantityPriceExchange
2 Nov 2012 THE ROYAL BANK OF SCOTLAND ASIA MERCHANT BANK SINGAPORE LT Block Buy 1,189,625 91.0000 BSE
2 Nov 2012 ABN AMRO BANK NV Block Sell 1,189,625 91.0000 BSE
2 Nov 2012 ABN AMRO BANK NV Bulk Sell 1,189,625 91.0000 BSE
2 Nov 2012 THE ROYAL BANK OF SCOTLAND ASIA MERCHANT BANK SINGAPORE LT Bulk Buy 1,189,625 91.0000 BSE
25 Oct 2012 THE ROYAL BANK OF SCOTLAND ASIA MERCHANT BANK SINGAPORE LT Block Buy 1,100,000 82.0000 BSE
25 Oct 2012 ABN AMRO BANK NV Block Sell 1,100,000 82.0000 BSE
25 Oct 2012 ABN AMRO BANK NV Bulk Sell 1,100,000 82.0000 BSE
25 Oct 2012 THE ROYAL BANK OF SCOTLAND ASIA MERCHANT BANK SINGAPORE LT Bulk Buy 1,100,000 82.0000 BSE
31 Mar 2006 PURAN ASSOCIATES PVT. LTD Bulk Sell 1,000,000 51.7000 BSE
31 Mar 2006 RATNA COMMERCIAL ENTERPRI Bulk Buy 1,000,000 51.7000 BSE

All bulk and block deals →

Ex-dateSubjectPer share (₹)Record date
29 Jun 2006 Agm/Dividend-20% — —
8 Jul 2005 Dividend-10% — —

Corporate Actions

Full history (9 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
25 Jul 2013OTHERAnnual General Meeting
26 Jul 2012OTHERAnnual General Meeting
28 Jul 2011OTHERAnnual General Meeting
15 Jul 2010OTHERAnnual General Meeting
13 Jul 2009OTHERAnnual General Meeting

All corporate actions →

Corporate Announcements

All 47 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
30 Dec 2013 Updates DSP Merrill Lynch Limited has submitted to the Exchange a copy of Exit offer Public Announcement made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("company") ("Delisting Offer").
20 Dec 2013 Delisting Fresenius Kabi Oncology Limited has, with reference to the Delisting of the equity shares of the Company from the Exchange, submitted to the Exchange the details of the name, address and contact numbers of the Contact Person at RTA and at the Company for solving Investor queries post Delisting.
20 Dec 2013 Suspension and Delisting of Trading in Equity Shares Members of the Exchange are hereby informed that the trading in the equity shares of Fresenius Kabi Oncology Limited shall be suspended w.e.f. January 03, 2014 (i.e. w.e.f. closing hours of trading on January 02, 2014 ) on account of voluntary delisting pursuant to the SEBI (Delisting of Equity Shares) Regulations, 2009. The admission to dealings in securities of the said company shall be withdrawn (delisted) w.e.f. January 10, 2014. Further, It may be noted that SEBI has informed the Exchange vide its letter dated December 20, 2013 that they have filed an appeal in this matter in the Hon ble Supreme Court and the outcome of the same is awaited.
12 Dec 2013 Resignation of Director Fresenius Kabi Oncology Limited has informed the Exchange that Dr. Patricia Grigoleit , Non-Executive Director of the Company, has resigned from the directorship of the Company with effect from December 11, 2013.
31 Oct 2013 Post Offer Public Announcement DSP Merrill Lynch Limited has submitted to the Exchange a copy Post offer Public Announcement ("Post Offer PA") is being issued by Fresenius Kabi (Singapore) Pte Ltd ("Acquirer") to the Public Shareholders of the Fresenius Kabi Oncology Limited ("Company"). This Post Offer PA is in continuation of and should be read in conjunction with, (i) the public announcement published on September 16, 2013 ( PA ) in respect of the proposed acquisition by the Acquirer and consequent delisting of the fully paid-up equity shares of the Company with a face value of Re. 1 each ("Shares") from the BSE Limited ( BSE ) and the National Stock Exchange of India Limited ( NSE ) in accordance with the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 ( Delisting Regulations ), and (ii) the letter of offer issued in respect thereof inviting Bids from all Public Shareholders of the Company ( Letter of Offer ), as amended by the first corrigendum to the PA and the Letter of Offer published on October 13, 2013, the second corrigendum to the PA and the Letter of Offer published on October 19, 2013 and the supplement to the second corrigendum (to the PA and the Letter of Offer) published on October 22, 2013. This Post Offer PA is being issued in accordance with Regulation 18 of the Delisting Regulations.
24 Oct 2013 Financial Result Updates Fresenius Kabi Oncology Limited has submitted to the exchange the standalone financial results for the period ended 30-sep-2013.
22 Oct 2013 Corrigendum DSP Merrill Lynch Limited has submitted to the Exchange a copy of the Supplement to the Second Corrigendum ("Corrigendum") to the Public Announcement issued pertaining to the delisting offer made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("Company") ("Delisting Offer").
21 Oct 2013 Updates Fresenius Kabi Oncology Limited has informed the Exchange that with reference to the earlier letter dated October 18, 2013, informing about the Securities Appellate Tribunal's (SAT) order dated October 18, 2013, granting the Company an extension of 2 months from October 22, 2013 for completing the Delisting Offer, Fresenius Kabi Oncology Ltd has now informed that the Company has on October 21, 2013 has received the copy of aforementioned SAT order dated October 18, 2013.
21 Oct 2013 Corrigendum DSP Merrill Lynch Limited has informed the Exchange regarding the Second Corrigendum ("Corrigendum") to the Public Announcement issued pertaining to the delisting offer made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("Company") ("Delisting Offer").
21 Oct 2013 Updates Fresenius Kabi Oncology Limited had informed the Exchange regarding the delisting update dated October 14, 2013. The Company has now informed the Exchange that the Company had filed a Miscellaneous Application No. 113 of 2013 in Appeal No. 133 of 2013 before the Hon'ble Securities Appellate Tribunal (SAT) seeking an extension of time to complete the Delisting Offer. The Hon'ble SAT disposed off the SAT Application on October 18, 2013. An order was passed in the open court granting the Company an extension of 2 months from October 22, 2013 for completing the Delisting Offer.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

Data unavailable.

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

Data unavailable.

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Fresenius Kabi Oncology Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.